Overview

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Status:
RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

This is a prospective single center phase IIa open label nonrandomized study, which aims to test the hypothesis that the duration of castration sensitive phase of stage IV prostate cancer can be prolonged with adaptive androgen deprivation therapy (ADT) and Docetaxel.

Phase:

PHASE2

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Treatments:

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
apalutamide
darolutamide
Docetaxel
enzalutamide
Gonadotropin-Releasing Hormone
Leuprolide
relugolix
Triptorelin Pamoate